Respiratory-Swallow Training and Variable Practice in Parkinson's Disease: A Clinical Trial Pilot Study.

Only 12 people were analysed out of 21 enrolled, because the COVID-19 shutdown closed the lab; the study had planned for 30. Only seven of the 12 reached the one-month follow-up. There was no untreated or alternative-treatment control group. The month-long pre-treatment baseline helps, but regression to the mean, placebo and non-specific effects cannot be ruled out. Everyone was at an early-to-mid stage of Parkinson's disease with moderate swallowing impairment, so this says little about people with severe or advanced disease. Feedback during training relied on the clinician's eyes rather than instrumentation, so what the clinician judged may not match what was measured. Swallowing was judged from video, not from direct measures of the underlying physiology such as laryngeal closure or pharyngeal pressure, so why safety improved is not known. No correction for multiple comparisons was made, and the authors describe every result as hypothesis-generating rather than as evidence of efficacy.

The authors declare no relevant financial or non-financial conflicts of interest. Funding came from a Clinical Research Training Scholarship in Parkinson's Disease from the American Brain Foundation, the Parkinson's Foundation and the American Academy of Neurology (Grant #2360), and partial support from the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health (Grant #F31DC0119281-01). No funder role in the design, conduct or reporting of the study is stated.

Do not read this as proof that four sessions of respiratory-swallow training improve swallowing safety in Parkinson's disease. There was no untreated control group, only 12 people were analysed, and the authors themselves call the results hypothesis-generating. Vocal fold residue also improved during the untreated month before training, which shows how much can change with no treatment at all.